All Stories

  1. TCT-128 TAVI/TAVR Device Capable of Heart Rhythm Pacing and Resynchronization Therapy

    Article • Journal of the American College of Cardiology, October 2024, Elsevier

    Dr. Eric Rytkin

  2. Endovascular occlusion of patent foramen ovale as antiarrhythmic treatment of atrial fibrillation

    Article • Journal of Interventional Cardiac Electrophysiology, July 2024, Springer Science + Business Media

    Dr. Eric Rytkin

  3. Comprehensive Analysis of Anticoagulant Therapy in Patients With Isolated Atrial Flutter

    Article • The American Journal of Cardiology, July 2024, Elsevier

    Dr. Eric Rytkin

  4. A Sewing Approach to the Fabrication of Eco/bioresorbable Electronics (Small 49/2023)

    Article • Small, December 2023, Wiley

    Dr. Eric Rytkin

  5. Ryanodine receptor inhibition with acute dantrolene treatment reduces arrhythmia susceptibility in human hearts

    Article • AJP Heart and Circulatory Physiology, October 2023, American Physiological Society

    Dr. Eric Rytkin

  6. Esmolol Facilitates Prolonged Conduction Preservation in the Ex Vivo Heart Studies

    Article • Cardiovascular Revascularization Medicine, August 2023, Elsevier

    Dr. Eric Rytkin

  7. MicroRNAs as Novel Biomarkers to Guide DAPT After PCI – Preliminary Assessment

    Article • Cardiovascular Revascularization Medicine, August 2023, Elsevier

    Dr. Eric Rytkin

  8. A Sewing Approach to the Fabrication of Eco/bioresorbable Electronics

    Article • Small, August 2023, Wiley

    Dr. Eric Rytkin

  9. Soft, bioresorbable, transparent microelectrode arrays for multimodal spatiotemporal mapping and modulation of cardiac physiology

    Article • Science Advances, July 2023, American Association for the Advancement of Science

    Dr. Eric Rytkin

  10. Editorial: The utilization of bench-to-bedside approaches in pharmacogenomics

    Article • Frontiers in Pharmacology, June 2023, Frontiers

    Dr. Eric Rytkin

  11. CRT-500.17 Esmolol Facilitates Prolonged Conduction Preservation in the Ex Vivo Heart Studies

    Article • JACC Cardiovascular Interventions, February 2023, Elsevier

    Dr. Eric Rytkin

  12. CRT-100.25 MicroRNAs as Novel Biomarkers to Guide DAPT After PCI – Preliminary Assessment

    Article • JACC Cardiovascular Interventions, February 2023, Elsevier

    Dr. Eric Rytkin

  13. MicroRNAs as Novel Biomarkers for P2Y12 – Inhibitors Resistance Prediction

    Article • Pharmacogenomics and Personalized Medicine, December 2021, Taylor & Francis

    Dr. Eric Rytkin

  14. MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring

    Article • Drug Metabolism and Personalized Therapy, August 2021, De Gruyter

    Dr. Eric Rytkin

  15. MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring

    Article • Drug Metabolism and Personalized Therapy, August 2021, De Gruyter

    Dr. Eric Rytkin

  16. Drug–drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation

    Article • Drug Metabolism and Personalized Therapy, September 2020, De Gruyter

    Dr. Eric Rytkin

  17. Drug–drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation

    Article • Drug Metabolism and Drug Interactions, September 2020, De Gruyter

    Dr. Eric Rytkin

  18. Selection of miRNAs for clopidogrel resistance prediction

    Article • Meta Gene, September 2020, Elsevier

    Dr. Eric Rytkin

  19. Clinically relevant pharmacogenetic markers in Tatars and Balkars

    Article • Molecular Biology Reports, April 2020, Springer Science + Business Media

    Dr. Eric Rytkin

  20. <p><em>CYP2C19*17</em> May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban</p>

    Article • Pharmacogenomics and Personalized Medicine, January 2020, Taylor & Francis

    Dr. Eric Rytkin

  21. Clinical pharmacology technologies for personalization of cardiovascular diseases drug treatment: focus on direct oral anticoagulants

    Article • Annals of the Russian academy of medical sciences, December 2019, Paediatrician Publishers LLC

    Dr. Eric Rytkin

  22. Micro-RNA as a new biomarker of activity of the cytochrome system P-450: significance for predicting the antiplatelet action of P2Y12 receptor inhibitors

    Article • Terapevticheskii arkhiv, August 2019, LLC Obyedinennaya Redaktsiya

    Dr. Eric Rytkin

  23. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes

    Article • Drug Metabolism and Personalized Therapy, July 2018, De Gruyter

    Dr. Eric Rytkin

  24. Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients?

    Article • Pharmacogenomics and Personalized Medicine, September 2017, Dove Medical Press

    Professor Dmitry Alexeevich Sychev, Dr. Eric Rytkin

  25. Assessment of CYP2C19, ABCB1, CYP3A5 Genes Polymorphisms’ and CYP3A4 Isoenzyme Activity Influence on Major Adverse Cardiovascular Events Among Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

    Article • Clinical Therapeutics, August 2017, Elsevier

    Dr. Eric Rytkin

  26. An Intracardiac Soft Robotic Device for Augmentation of Blood Ejection from the Failing Right Ventricle

    Article • Annals of Biomedical Engineering, May 2017, Springer Science + Business Media

    Dr. Eric Rytkin

  27. CRT-100.09 The Impact of CYP2C19, ABCB1 Genes Polymorphisms and CYP3A4 Isoenzyme Activity on the Incidence of Stent Implantation Complications for Patients With an Acute Coronary Syndrome

    Article • JACC Cardiovascular Interventions, February 2017, Elsevier

    Dr. Eric Rytkin